Modi-2 a vaccine stimulating CD4 responses to homocitrullinated self epitopes as therapy for solid cancers
Abdullah A. Al-Omari, Katherine W. Cook, Peter Symonds, Anne Skinner, Alissa Wright, Yaling Zhu, Vincent L. Coble, Omar J. Mohammed, Ruhul H. Choudhury, Nazim Uddin, Priscilla Ranglani, Adrian Parry, Sally E. Adams, Geoffrey M. Lynn, Lindy G. Durrant, Victoria A. Brentville · 2024
Read Modi-2 a vaccine stimulating CD4 responses to homocitrullinated self epitopes as therapy for solid cancers by Abdullah A. Al-Omari, Katherine W. Cook, Peter Symonds, Anne Skinner, Alissa Wright, Yaling Zhu, Vincent L. Coble, Omar J. Mohammed, Ruhul H. Choudhury, Nazim Uddin, Priscilla Ranglani, Adrian Parry, Sally E. Adams, Geoffrey M. Lynn, Lindy G. Durrant, Victoria A. Brentville (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11603156.txt.
Introduction
Abdullah Al-Omari and a large team build a cancer vaccine from altered self-proteins. Their study from twenty twenty-four presents the Modi-2 vaccine. Tumour stress converts a common amino acid into a new form. That change creates targets the immune system can finally see.
Four altered peptides ride inside self-assembling nanoparticles. The particles carry an immune booster in precise amounts. Helper T-cell responses are the vaccine main goal. Mouse tumours of three types shrank under vaccine attack. Melanoma, bowel, and breast models all responded significantly. Manufacturing ease was designed in from the start. Human trials are the logical next step for this platform.
Catalog record
| CREATOR | Abdullah A. Al-Omari, Katherine W. Cook, Peter Symonds, Anne Skinner, Alissa Wright, Yaling Zhu, Vincent L. Coble, Omar J. Mohammed, Ruhul H. Choudhury, Nazim Uddin, Priscilla Ranglani, Adrian Parry, Sally E. Adams, Geoffrey M. Lynn, Lindy G. Durrant, Victoria A. Brentville |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 58 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Modi-2 a vaccine stimulating CD4 responses to homocitrullinated self epitopes as therapy for solid cancers Authors: Abdullah A. Al-Omari, Katherine W. Cook, Peter Symonds, Anne Skinner, Alissa Wright, Yaling Zhu, Vincent L. Coble, Omar J. Mohammed, Ruhul H. Choudhury, Nazim Uddin, Priscilla Ranglani, Adrian Parry, Sally E. Adams, Geoffrey M. Lynn, Lindy G. Durrant, Victoria A. Brentville Published: 2024 ABSTRACT Stresses within the tumour microenvironment can mediate post-translational modifications of self-proteins. Homocitrullination is the conversion of lysine to homocitrulline which generates neoepitopes and bypasses self-tolerance. In this study a vaccine targeting homocitrullinated antigens was assessed for stimulation of anti-tumour immunity. Peptides that bind HLA are often hydrophobic which can complicate large scale manufacture and solubility. Here we demonstrate the self-assembling nanoparticle technology (SNAPvaxTM) to co-deliver four homocitrullinated peptides and adjuvant in nanoparticles of a precise size and composition as a vaccine (“Modi-2”) that is optimized for manufacturing ease and T cell induction. Strong T cell responses and anti-tumour immunity in mouse tumour models was stimulated against against B16 melanoma (p = 0.0113), CT26 colorectal cancer (p < 0.0001) and 4T1 breast cancer (p = 0.0090). We demonstrate that human lung, colorectal, breast and prostate tumours express the Modi-2 target antigens and propose the Modi-2 vaccine has potential for translation into clinic in several cancer indications. Introduction The cellular stress of the tumour microenvironment (TME) can induce post-translational modifications (PTMs) of proteins that can appear foreign to the immune and be recognized as antigens1. One such PTM is homocitrullination or carbamylation which is the conversion of lysine residues to homocitrulline. This results in the conversion of a positively charged amino acid lysine into a neutral amino acid homocitrulline and can result in altered MHC binding properties2. The conversion of lysine to homocitrulline is driven by the accumulation of cyanate3,4, which under inflammatory conditions, is driven by the myeloperoxidase (MPO) enzyme. We have previously demonstrated a role for MPO-producing tumour-associated myeloid derived suppressor cells (MDSCs) in MPO production which in combination with tumour produced H2O2 leads to homocitrullination within the tumour microenvironment5. Mutational neo-antigens that also are not subject to immune tolerance are linked to the success of checkpoint blockade therapies in several indications and are showing promising results as targets for vaccination6–8. However, many cancers do not possess a high mutational burden and show limited efficacy to checkpoint blockade therapies. Stress-related PTMs alter proteolytic cleavage and can generate neoantigens or neoepitopes which evade self-tolerance9,10. In this scenario these cancers may benefit from de novo induction of PTM specific T cell responses via vaccination. Vaccination targeting homocitrullinated peptides derived from self-antigens has been shown to stimulate Th1 mediated immune responses in mouse models and mediate tumour therapy5,11. Many cancer vaccines have been focussed on the stimulation of CD8 T cell responses and their role in tumour therapy rather than CD4 responses although the important role of CD4 T cells is now becoming more apparent12,13. CD4 T cells play an important role in cancer therapy and can either directly mediate the destruction of established tumours14,15 and/or indirectly by their interaction with APCs which induces the release of interferons that then upregulate MHC-I/II and stimulate the release of pro-inflammatory chemokines to promote further immune infiltration13,16. The efficacy of a peptide vaccine is also enhanced if combined with a costimulatory adjuvant. Toll-like receptor (TLR) ligand stimulation in combination with vaccination has been shown to increase vaccine efficacy, especially for cancer therapy17. Despite many early phase trials with new TLR ligand adjuvants only a few have been approved for use in humans. We and others have demonstrated in preclinical models the benefit of combining a peptide vaccine with a TLR ligand adjuvant to promote CD8 and CD4 T cell responses18–21. TLR ligands that stimulate strong Th1 immunity are often hydrophobic in nature and combined with hydrophobic nature of MHC binding peptides can lead to challenges for large scale manufacture and sterile filtration. The SNAPvax technology which enables formulation of hydrophobic MHC binding peptides with TLR 7/8 ligand that self assembles into nanoparticles has demonstrated superior immunogenicity and stimulation of CD8 T cell responses. Antigen delivered in this particulate form not only persisted longer at the dosing site but was also associated with uptake by APCs in draining lymph nodes21,22. In mouse models, no evidence of systemic localisation is noted unless delivered via an intravenous route23. Here we demonstrate the combination of four homocitrullinated peptides from self-antigens, vimentin, aldolase A, Binding Immunoglobulin Protein (BiP) which is also known as “GRP78” and cytokeratin 8, combined with TLR ligand adjuvant as a peptide vaccine (Modi-2) stimulates strong Th1 mediated anti-tumour responses in mouse models. We further show that the formulation characteristics of the Modi-2 vaccine can be improved using SNAPvax technology wherein each of the homocitrullinated peptides were synthesized as amphiphiles linked to TLR ligand and self-assemble into nanoparticles of precise size and composition co-delivering the four peptides and TLR ligand for induction of CD4 T cell responses and tumour therapy. Finally, we highlight the expression of the self-antigens and MPO in solid tumours and association with prognosis and propose using the SNAPvax technology for targeting of homocitrullinated self-antigens via vaccination for solid tumour therapy. Results Responses to homocitrullinated peptides can be stimulated in mice and are CD4 mediated Proteins containing homocitrulline modifications are known to be immunogenic. We have previously shown that homocitrullinated (Hcit) peptides derived from aldolase A (Aldo), immunoglobulin heavy chain-binding protein (BiP), cytokeratin 8 (Cyk8) and vimentin (Vim) can stimulate CD4 T cell responses through multiple MHCII alleles in standard and HLA transgenic mice including HLA-HHDII/DR1, HLA-HHDII/DP4, HLA-DR4 and Balb/c mice. We have also observed that among several peptides screened, Aldo74-93Hcit, BiP562-579Hcit, Cyk8 371-388Hcit and Vim116-135Hcit peptides induced T cell responses in the different mouse strains mentioned above5,11. These epitopes are homologous in humans and mice. In this study we first aimed to confirm whether vaccination of Aldo74-93Hcit, BiP562-579Hcit, Cyk8 371-388Hcit and Vim116-135Hcit in combination (known as Modi-2) mixed with CpG and MPLA adjuvants would induce T cell responses in different mice strains. A schematic of the immunisation regime is shown in Fig. 1A. HLA-HHDII/DP4 and Balb/c mice immunised with the Modi-2 peptide combination were screened for peptide specific responses in IFNγ ELISpot assay. This screening showed significant responses to Aldo74-93Hcit (p = 0.0005), Bip562-579Hcit (p < 0.0001) and Vim116-135Hcit (p = 0.0472) in HLA-HHDII-DP4 mice (Fig. 1B). However no immune responses to Cyk8 371-388Hcit were observed in HLA-HHDII-DP4 mice. Balb/c mice induced significant immune responses to Aldo74-93Hcit (p = 0.0042), Cyk8 371-388Hcit (p = 0.0021) and Vim116-135Hcit (p = 0.0014). However, no immune responses to Bip562-579Hcit were identified in Balb/c mice (Fig. 1E). Mice immunised with the CpG and MPLA adjuvants alone, irrelevant peptide in CpG and MPLA or naïve mice failed to show any reactivity to the Hcit peptides (Supplementary Fig. 1).Fig. 1Modi-2 peptides elicit Hcit specific CD4 mediated responses in mice.Schematic of immunisation regime (A). T cell responses to the Modi-2 peptides and counterpart wild type peptides in HLA-HHDII/DP4 (B–D) and Balb/c mice (E–H). Mice were vaccinated with three doses of homocitrullinated peptides mixed with the adjuvants CpG and MPLA and responses assessed against Hcit peptides (B, E), Hcit and wt peptides (C, F) or Hcit peptides in presence of CD4 or